DN-108, a thiazolidinedione derivative, is an orally active peroxisome proliferator-activated receptor gamma (PPARgamma) agonist with antidiabetic effects. DN-108 improves hyperglycemia, hypertriglyceridemia and hyperinsulinemia in diabetic mouse models. DN-108 enhances tissue glucose uptake (e.g., increasing 2-deoxyglucose uptake in L6 muscle cells) and inhibits fatty acid synthase activity. DN-108 is promising for research of type 2 diabetes[1].
Molekulargewicht:
366.43
CAS Nummer:
[195604-21-8]
Formel:
C20H18N2O3S
Target-Kategorie:
PPAR
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
